On January 3, 2023, the U.S. Food and Drug Administration (“FDA”) released an updated Mifepristone Risk Evaluation and Mitigation Strategy (the “Mifepristone REMS Program”), which reverses the requirement that the drug be dispensed directly to a patient by certified prescriber in a clinic or a medical office (the “in-person dispensing requirement”). The updated Mifepristone REMS…Read More
FDA Expands Access to Mifepristone: Next Steps for Providers and Retail Pharmacies
Posted on February 7, 2023 in Health Law News
Published by: Hall Render